HepaRegeniX is a series b startup based in Germany. 1 investor tracked.
HepaRegeniX is a company founded in 2017 headquartered in Germany. Its most recent tracked round is Series B. Brouky records 4 investors associated with the company.
HepaRegeniX is a biopharmaceutical company developing novel small molecule therapeutics to stimulate liver regeneration. Their lead compound, HRX-215, targets the MKlp2 protein for the treatment of acute and chronic liver diseases.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.